Biohaven CEO Vlad Coric (Photo Credit: Andrew Venditti)
Biohaven continues push for oral migraine med Nurtec amid new portfolio line up
Biohaven is spending to move the oral migraine drug market — and it seems to be working. The biopharma reported $463 million in Nurtec sales for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
